1
|
Fattizzo B, Rizzo L, Giannotta JA, Mazzon F, Cecchi N, Frangi C, Barcellini W, Riva M. Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon? Br J Haematol 2021; 195:e147-e150. [PMID: 34312838 DOI: 10.1111/bjh.17722] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 12/18/2022]
Affiliation(s)
- Bruno Fattizzo
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Oncology and Oncohematology, University of Milan, Milan, Italy
| | - Lorenzo Rizzo
- Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy
| | | | - Federico Mazzon
- Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy
| | - Nicola Cecchi
- Department of Oncology and Oncohematology, University of Milan, Milan, Italy
| | - Claudia Frangi
- Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy
| | - Wilma Barcellini
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Marta Riva
- Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy
| |
Collapse
|